Newsroom
Contact us
FAQ
Íslenska
  • Company
  • For investors
  • Biosimilars
  • Corporate Sustainability
  • Careers
Company Announcement
17 March 2023

Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting

Alvotech to present two posters related to pharmacokinetics and confirmatory clinical studies for AVT04 (ustekinumab), a proposed biosimilar to Stelara® Marketing applications for AVT04 have been...
Financial Reports
01 March 2023

Alvotech Reports Financial Results for Full Year 2022 and Provides Business Update

Full year 2022 total revenue, including other income, increased by 114% to $85.0 million, compared to $39.7 million in 2021, driven by both milestone revenue and product revenue from commercialization...
Company Announcement
28 February 2023

Alvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results...
Company Announcement
14 February 2023

Updated market making agreement with Landsbankinn for Alvotech shares trading on the Nasdaq Iceland market

Alvotech (Nasdaq: ALVO) and Landsbankinn hf. have updated their market making agreement, which has been in effect since Alvotech’s shares were admitted to trading in Iceland on June 23, 2022. The...
Company Announcement
10 February 2023

Settlement of Alvotech Private Share Placement Completed

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today the completion of the equity...
Company Announcement
09 February 2023

EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)

Partners Alvotech and STADA have marketing authorization application (MAA) for ustekinumab accepted for filing by the European Medicines Agency (EMA) EMA opinion on AVT04 could come as soon as the...
Company Announcement
06 February 2023

Alvotech enters into commercialization agreement with Advanz Pharma for proposed biosimilar to Xolair® (omalizumab)

Advanz Pharma will commercialize AVT23, a proposed biosimilar to Xolair® (omalizumab) in the European Economic Area, UK, Switzerland, Canada, Australia, and New Zealand Alvotech (NASDAQ: ALVO), a...
Company Announcement
24 January 2023

Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia

AVT02 as Simlandi™ is the first biosimilar approved under the strategic partnership between Alvotech and Bioventure Alvotech (NASDAQ: ALVO) and Bioventure, a wholly owned subsidiary of GlobalOne...
Inside information
23 January 2023

Alvotech Completes $137 Million Private Share Placement

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completion of a private placement...
Inside information
20 January 2023

Alvotech initiates proposed private share placement to professional clients and eligible counterparties in Iceland

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today confirmed the initiation of a proposed private placement of ordinary shares, made in an overseas directed offering, directed solely into Iceland to
1…2223…32
  • About Us
  • Media Center
  • Careers
  • Newsroom
  • Contact us
  • Terms of Use
  • Privacy Policy
  • Cookie Policy

Alvotech 2025. All rights reserved.